CureVac is going from being one of the quietest players in the race to develop a new vaccine to fight the worst public health crisis in a century to a challenger for the multibillion-dollar market that awaits the first vaccines to make it over the finish line. Typically low-key at
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters…
Jamie Dimon says the U.S. consumer is in good shape right now, but a huge fiscal deficit and geopolitical challenges make him cautious about the…
Roche has axed one-fifth of its pipeline since the third quarter of 2023 as part of a broader portfolio review aimed at boosting the company’s…
A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to reinvent drug…
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s disease. Patients…
Her intentions, revealed in a public filing, comes after the once-hot company’s valuation collapsed from a high of $6 billion.
Boehringer Ingelheim put the spotlight on a pipeline ripe with milestones over the next decade during its full-year 2023 earnings call with the press. Driven…
Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena. The New York pharma will commit $100 million per…
